Facilitated thrombolysis: Dethrombosis?

Clinical and Applied Thrombosis/Hemostasis

Volumn 8, Issue 2, 2002, Pages 133-138

  Luciardi, Héctor ^a   Berman, Sofía ^a   Muntaner, Juan ^a   De la Serna, Fernando ^a   Altman, Raúl ^a  

^a UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

Fibrin; Fibrinolysis; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTIFIBRINOLYTIC AGENT; ANTITHROMBOCYTIC AGENT; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; RECEPTOR BLOCKING AGENT; RETEPLASE; TENECTEPLASE; TIROFIBAN; UNCLASSIFIED DRUG; HEMATOLOGIC AGENT;

ACUTE HEART INFARCTION; ARTICLE; BLOOD CLOT LYSIS; CELL INTERACTION; CLINICAL TRIAL; DISSOLUTION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; FIBRIN FORMATION; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; PRIORITY JOURNAL; REPERFUSION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY; METHODOLOGY; REVIEW; THROMBOSIS;

FIBRINOLYSIS; HEMATOLOGIC AGENTS; HUMAN; REPERFUSION; THROMBOLYTIC THERAPY; THROMBOSIS; HUMANS;

EID: 0035992763     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960200800208     Document Type: Article

References (53)

1. El mecanismo de la hemostasia normal. Cuadernos de trombosis. Infomed
2. Rapid and sustained coronary artery recanalization with combined bolus injection of rt-PA and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation
3. Remodelado del trombo: Punto clave en la progresioón de la ateroesclerosis coronaria
4. Coronary plaque disruption
5. Abciximab in the treatment of AMI eligible for primary percutaneous transluminal coronary angioplasty. Results of the glycoprotein receptor antagonist patency evaluation (GRAPE) pilot study
6. Secondary prevention of myocardial infarction. Beneficial effect of combining oral anticoagulant plus aspirin: Therapy based on evidence
7. Coronary angioscopic findings in the infarct-related vessel within 1 month of acute myocardial infarction. Natural history and the effect of thrombolysis
8. Direct thrombin inhibition superior to heparin during and after thrombolysis. Dose, duration and drug
9. Abciximab facilitates the rate and extent of thrombolysis. Results of the TIMI-14 Trial
10. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence
11. GP IIb/IIIa antagonists: Pathophysiologic and therapeutic insights from studies of c7E3 Fab
12. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17.187 cases of suspected AMI: ISIS-2
13. Fibrin-Fibrinogen and dethrombosis
14. Thrombolysis for acute myocardial infarction
15. Thrombosis and thrombolysis in unstable angina
16. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina. Results of the TAUSA trial
17. Enhancement of thrombolysis with tissue-type plasminogen activator by pre-treatment with heparin
18. Effects of standard heparin and a low molecular heparin on fibrinolysis
19. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: Results of the heparin in early patency (HEAP) pilot study
20. Confirmation that heparin is an alternative means of promoting early reperfusion
21. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I trial
22. Relation between activated clotting time during angioplasty and abrupt closure
23. Angiographic monitoring of reperfusion therapy for AMI: TIMI grade 3 perfusion is the goal
24. The development of hirudin as an antithrombotic drug
25. Dissolution of mural thrombus by specific thrombin inhibition with rhirudin: Comparison with heparin and aspirin
26. Does antithromboric therapy influence residual thrombus after thrombolysis of platelet-rich thrombus?: Effects of r-hirudin, heparin, or aspirin
27. Reversibility of platelet thrombosis in vivo. Quantitative analysis in porcine carotid arteries
28. Monitoring platelet function in glycoprotein IIb/IIIa inhibitor therapy
29. Integrin signaling: The platelet paradigm
30. The antiplatelet effects of ticlopidin and clopidogrel
31. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes
32. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
33. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
34. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina receptor suppression using integrelin therapy
35. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofibanin unstable angina and non-Q-wave myocardial infarction. Platelet receptor inhibition in ischemic syndromes management in patients limited by unstable signs and symptoms (PRISM-PLUS) study investigators
36. In vivo demonstration of an antithrombin effect of abciximab
37. Progress in the treatment of ACS. A 50-year perspective (1950-2000)
38. IIb/IIIa in acute coronary syndromes: An evidenced-based approach
39. Augmentation of thrombolysis with antiplatelet drugs: Overview
40. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention
41. Restoration of coronary flow in MI by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: Observations in animals and humans
42. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the TAMI 8 pilot study
43. Combined accelerated t-PA and platelet GP IIb/IIIa integrin receptor blockade with integrilin in AMI
44. More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: The PARADIGM trial
45. Emergency room infusion of abciximab speeds up reperfusion in AMI eligible for primary PTCA
46. IIb/IIIa receptor antagonists for failed rescue angioplasty
47. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in AMI. Results from the SPEED (GUSTO-4 Pilot) trial
48. A clinical trial comparing primary coronary angioplasty with tPA for MI
49. Thrombolysis in MI (TIMI) trial, phase I: A comparison between intravenous tPA and intravenous SK
50. Reperfusion therapy for AMI with fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomized trial
51. GUSTO V: The bottom line of fibrinolytic reperfusion therapy
52. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 trial in AMI
53. Defibrinogenating enzymes